Northern Trust’s Repare Therapeutics RPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-260,311
| Closed | -$677K | – | 4514 |
|
|
2025
Q4 | $677K | Sell |
260,311
-1,890
| -0.7% | -$3.81K | ﹤0.01% | 3540 |
|
|
2025
Q3 | $461K | Sell |
262,201
-23,809
| -8% | -$38.1K | ﹤0.01% | 3676 |
|
|
2025
Q2 | $398K | Sell |
286,010
-6,350
| -2% | -$8.28K | ﹤0.01% | 3723 |
|
|
2025
Q1 | $288K | Buy |
+292,360
| New | +$352K | ﹤0.01% | 3803 |
|
|
2023
Q4 | – | Sell |
-14,710
| Closed | -$178K | – | 4527 |
|
|
2023
Q3 | $178K | Sell |
14,710
-7,439
| -34% | -$76.8K | ﹤0.01% | 3864 |
|
|
2023
Q2 | $234K | Sell |
22,149
-55
| -0.2% | -$567 | ﹤0.01% | 3764 |
|
|
2023
Q1 | $218K | Sell |
22,204
-743
| -3% | -$8.52K | ﹤0.01% | 3820 |
|
|
2022
Q4 | $338K | Buy |
22,947
+1,046
| +5% | +$15.6K | ﹤0.01% | 3634 |
|
|
2022
Q3 | $265K | Buy |
21,901
+628
| +3% | +$8.08K | ﹤0.01% | 3733 |
|
|
2022
Q2 | $298K | Buy |
21,273
+649
| +3% | +$7.64K | ﹤0.01% | 3728 |
|
|
2022
Q1 | $294K | Sell |
20,624
-367
| -2% | -$5.44K | ﹤0.01% | 3958 |
|
|
2021
Q4 | $442K | Buy |
20,991
+5,161
| +33% | +$122K | ﹤0.01% | 3855 |
|
|
2021
Q3 | $415K | Buy |
15,830
+233
| +1% | +$7.53K | ﹤0.01% | 3837 |
|
|
2021
Q2 | $487K | Buy |
+15,597
| New | +$511K | ﹤0.01% | 3718 |
|
Northern Trust's RPTX Position: Q1 2026 in Review
Northern Trust sold out of Repare Therapeutics (RPTX) in Q1 2026, closing a stake of 260,311 shares — an estimated $677K sold.
Northern Trust first reported a position in RPTX in Q2 2021 and held it in 14 quarters. The position peaked at $677K in Q4 2025. 0 funds tracked by Wall St. Rank hold RPTX as of Q1 2026.
- Northern Trust reported no remaining Repare Therapeutics position as of Q1 2026 after selling out during the quarter.
- Northern Trust sold 260,311 Repare Therapeutics shares in Q1 2026, an estimated $677K.
- Northern Trust first reported a position in Repare Therapeutics in Q2 2021 and held it in 14 quarters.
- Northern Trust's Repare Therapeutics position peaked at $677K in Q4 2025.
- 0 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2026.
Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.